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ACKGROUND: Over the past 50 years, scientists 
have recognized that not all adipose tissue is alike, 
and that health risk is associated with the location 
as well as the amount of body fat. Different depots are 
suficiently distinct with respect to fatty-acid storage 
and release as to probably play unique roles in human 
physiology. Whether fat redistribution causes metabolic 
disease or whether it is a marker of underlying processes 
that are primarily responsible is an open question.
CONTENT: The limited expandability of the subcutaneous 
adipose tissue leads to inappropriate adipose cell expansion 
(hypertrophic obesity) with local inlammation and a 
dysregulated and insulin-resistant adipose tissue. The 
inability to store excess fat in the subcutaneous adipose 
tissue is a likely key mechanism for promoting ectopic fat 
accumulation in tissues and areas where fat can be stored, 
including the intra-abdominal and visceral areas, in the liver, 
epi/pericardial area, around vessels, in the myocardium, 
and in the skeletal muscles. Many studies have implicated 
ectopic fat accumulation and the associated lipotoxicity as 
the major determinant of the metabolic complications of 
obesity driving systemic insulin resistance, inlammation, 
hepatic glucose production, and dyslipidemia.
SUMMARY: In summary, hypertrophic obesity is due to an 
impaired ability to recruit and differentiate available adipose 
precursor cells in the subcutaneous adipose tissue. Thus, the 
subcutaneous adipose tissue may be particular in its limited 
ability in certain individuals to undergo adipogenesis 
during weight increase. Inability to promote subcutaneous 
adipogenesis under periods of afluence would favor lipid 
overlow and ectopic fat accumulation with negative 
metabolic consequences.
L
ATAR BELAKANG: Telah lebih dari 50 tahun, 
para peneliti menyadari bahwa tidak semua 
jaringan adiposa adalah sama, dan bahwa risiko 
kesehatan berhubungan dengan jumlah dan lokasi adiposa 
tubuh. Perbedaan lokasi penyimpanan adiposa ini berkenaan 
dengan penyimpanan dan pelepasan asam adiposa sehingga 
dapat memainkan peran yang unik pada isiologi manusia. 
Bagaimana redistribusi adiposa dapat menyebabkan 
penyakit metabolik, atau apakah hal ini merupakan penanda 
yang mendasari proses utama terjadinya penyakit, masih 
merupakan tanda tanya.
ISI: Kemampuan ekspansi jaringan adiposa subkutan yang 
terbatas, memicu terjadinya ekspansi sel adiposa yang tidak 
tepat (obesitas hipertroi) disertai inlamasi lokal, disregulasi 
jaringan adiposa dan resistensi insulin. Ketidakmampuan 
menyimpan kelebihan adiposa pada jaringan adiposa 
subkutan merupakan mekanisme kunci yang mengawali 
akumulasi adiposa ektopik pada jaringan dan area dimana 
adiposa dapat disimpan, termasuk area intra-abdominal dan 
viseral, hati, area epi/perikardial, sekitar pembuluh darah, 
miokardium, dan otot skeletal. Banyak penelitian yang 
menunjukkan hubungan akumulasi adiposa ektopik dengan 
lipotoksisitas sebagai penentu utama komplikasi metabolik 
pada obesitas yang menyebabkan resistensi insulin sistemik, 
inlamasi, produksi glukosa hepatik, dan dislipidemia.
RINGKASAN: Secara ringkas, obesitas hipertroi berkaitan 
dengan ketidakmampuan sel prekursor adiposa yang 
tersedia pada jaringan adiposa subkutan untuk merekrut 
dan berdiferensiasi. Dengan demikian, jaringan adiposa 
subkutan memiliki keterbatasan dalam hal adipogenesis 
selama proses peningkatan beran badan. Ketidakmampuan 
untuk meningkatkan adipogenesis subkutan pada periode 
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Introduction
of the subcutaneous adipose tissue, which, when exceeded, 
promotes ectopic fat accumulation and metabolic 
complications.
Adipose tissue can be divided into two major types: white 
adipose tissue (WAT) and brown adipose tissue (BAT), both 
of which have different physiological roles ascribed to them. 
Subcutaneous adipose tissue (SAT) and visceral adipose 
tissue (VAT) are two types of WAT. Although it has been 
reported that SAT is less metabolically active than VAT, it is 
an important storage organ, implicated in the accumulation 
of triacylglycerols (TGs) during periods of excess energy 
intake, and the supply of free fatty acids (FFAs) during 
periods of fasting, starvation, or exercise. SAT also serves 
as a buffer during intake of dietary lipids and thus protects 
other tissues from lipotoxic effects of these lipids.(11) VAT 
can be omental or mesenteric, and it surrounds various inner 
organs in humans. The omental fat depot covers the stomach 
and spleen and extends into the ventral abdomen, while the 
mesenteric depot is attached to the intestine.(12) BAT is 
found in deined and dispersed areas in the body such as 
clavicular, supraclavicular, and subscapular regions (10) or 
as clusters within WAT in different animals.(13) The main 
role of BAT is reported to be nonshivering thermogenesis 
in mammals, with this role in humans being particularly 
important in neonates.(14)
 Human epicardial adipose tissue (EAT) is a visceral 
thoracic fat depot with proximity to the heart, and is located 
along the large coronary arteries and on the surface of 
ventricles and the apex of the heart.(15-17) EAT has been 
deined as the intrapericardial fat depot that is located 
between the myocardium and visceral pericardium, while 
the storage of TGs droplets within the cardiomyocytes have 
been termed myocardial fat.(18) The fat surrounding the 
vasculature has also been termed perivascular adipose tissue 
(PVAT), irrespective of location.(19)
 Marrow fat or marrow adipose tissue (MAT) is well 
established as a component of the bone marrow (BM) 
environment, but its function remains unknown. In clinical 
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yang lama akan menimbulkan luapan adiposa dan 
akumulasi adiposa ektopik, dengan konsekuensi metabolik 
yang negatif.
KATA KUNCI: obesitas, adipogenesis, jaringan adiposa 
subkutan,  jaringan lemak viseral, disfungsi adiposit
The current global epidemic of obesity is a huge challenge 
to society and imposes increasing costs on the health care 
system because obesity is associated with several negative 
consequences to our health, including type 2 diabetes 
mellitus (T2DM), cardiovascular disease, and cancer.(1) 
However, it is not only the degree of obesity that is important 
but also the distribution of fat; an abdominal distribution 
augments the metabolic complications at a given body mass 
index (BMI).(2) This inding has raised much interest in 
the potential role of regional differences in adipose tissue 
metabolism and, in particular, the role of intra-abdominal 
and visceral fat in causing the metabolic complications.(3,4) 
However, increased amounts of intra-abdominal/visceral fat 
is also associated with other ectopic fat accumulations and 
may, thus, be a marker rather than causally related to the 
metabolic complications of obesity.(5)
 Certain subcutaneous fat regions appear to be 
metabolically, immunologically, and mechanically 
protective. Subcutaneous fat, which can expand outward 
without the anatomic constraints that limit visceral fat 
growth, is specialized to provide long-term fuel storage, 
acting as a sink to sequester potentially lipotoxic fatty 
acids.(6-8) Consistent with its role in energy storage, 
subcutaneous fat is the major source of leptin, which 
signals the state of lipid stores to the brain. Dysfunctional 
subcutaneous fat is associated with visceral fat enlargement, 
systemic inlammation, and lipotoxicity.(7) Interestingly, 
subcutaneous fat abundance increases when visceral 
fat is removed from experimental animals.(9) When 
subcutaneous fat is removed, visceral fat mass, insulin 
resistance, circulating insulin, and tumor necrosis factor 
(TNF)-a increase. This may contribute to the visceral fat 
enlargement that occurs in tandem with subcutaneous 
fat loss in lipodystrophies and aging or subcutaneous fat 
dysfunction in obesity.(10)
 Inappropriate expansion of the subcutaneous adipose 
cells leads to hypertrophic obesity characterized by a 
dysregulated adipose tissue with insulin resistance and 
inlammation. Here, we discuss the limited expandability 
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studies of healthy populations as well as in populations of 
individuals with metabolic disease, MAT has been shown 
to be inversely associated with measures of bone mineral 
density (BMD) and bone integrity and therefore may be an 
important regulator of bone turnover.(20)
 The principal function of adipose tissue is to store 
and release fat in response to energy-balance needs. 
Adipose tissue also has immune, endocrine, regenerative, 
mechanical, and thermal functions.(8) Both the fuel and 
nonfuel functions of adipose tissue vary among depots, with 
depot size, and with body-fat distribution. Potentially, when 
dysregulation of fatty-acid storage and release occurs in 
upper-body obesity, fatty-acid overlow into ‘‘ectopic’’ sites 
leads to lipotoxicity.(7) In addition to their role as major 
sources of cellular fuel, fatty acids can serve as signaling 
molecules in the form of diacylglycerols, ceramides, and 
long-chain acyl-coenzymes A. These molecules can exert 
adverse effects on cell function, including interference with 
insulin signaling, when present in excess.(10)
 During weight gain, different fat depots enlarge via 
hyperplasia, hypertrophy, or both.(21) New adipocytes 
can be generated more rapidly in some depots than 
others. Regional differences in preadipocyte replication, 
differentiation, subtype abundance, susceptibility to 
apoptosis or senescence, and gene expression may contribute 
to regional variation in fat-tissue function.(22)
 Obesity, aging, and lipodystrophies are associated 
with sustained fat-tissue immuneresponse activation, 
proinlammatory cytokine release, impaired insulin 
responsiveness, reduced incorporation of fatty acid as 
triglycerides, and increased lipolysis.(8,22) This contributes 
to low-grade ‘‘sterile’’ systemic inlammation, metabolic 
dysregulation, and lipotoxicity, with different fat depots 
potentially contributing in distinct ways.
WAT is perhaps the most plastic organ in the body, 
capable of regeneration following surgical removal and 
massive expansion or contraction in response to altered 
energy balance.(23) This striking degree of plasticity is 
unique among organs in adults. On a cellular level, WAT 
expansion is driven by both hypertrophy and hyperplasia of 
adipocytes.(24-30) Even in nonexpanding WAT, adipocytes 
renew frequently to compensate for adipocyte death, with 
approximately 10% of adipocytes renewed annually.(30,31) 
 Both adipocyte hypertrophy and hyperplasia occur 
during normal growth phases and during the development of 
obesity.(29,32-34) Hypertrophy often precedes hyperplasia 
in a cyclic manner. Hyperplasia, herein referred to as 
‘‘adipogenesis,’’ represents the complex process by which 
new fat cells are developed from adipocyte precursor fat 
cells called preadipocytes. Adipogenesis involves two major 
events - the recruitment and proliferation of preadipocytes 
followed by their subsequent differentiation into mature fat 
cells.(35-37) ‘‘Proliferation’’ refers to the process by which 
preadipocytes replicate so as to increase fat cell number, 
whereas ‘‘differentiation’’ refers to the process by which 
undifferentiated, proliferating ibroblast-like preadipocytes 
Figure 1.  Anatomy of major fat depots in rodents and humans.(10) (Adapted with permission from Elsevier).
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become permanently cell cycle - arrested, spherical, lipid-
illed and functionally mature fat cells.(35) Differentiation 
is accompanied by dramatic alterations in cell shape as well 
as by molecular changes that lead to dramatic increases in 
the ability of the cell for lipid synthesis and increases in 
hormonal responsiveness speciic to the specialized role of 
the adipocyte in energy homeostasis.(37-39)
 Following the development of methods for separating 
WAT into adipocyte and stromal vascular fractions (SVFs).
(40) Studies reported growth of ibroblast-like cells from 
the SVFs are capable of adipogenesis.(41-43) This led to 
the designation of these stromal vascular cells (SVCs) as 
“primary” preadipocytes, setting the stage for extensive 
characterization of the mechanisms regulating adipogenesis 
and WAT expansion.
 The use of cell lines has facilitated extensive 
investigation of adipogenesis on a molecular level, 
leading to detailed characterization of extracellular 
modulators, intracellular signaling pathways, and, notably, 
transcriptional mechanisms that impact and underlie 
adipocyte differentiation. These developments have been 
reviewed extensively elsewhere (44-48) and continue to be 
reined and extended to this day, especially through global 
proiling of epigenetic modiications and transcription factor 
binding sites using DNase hypersensitivity, chromatin 
immunoprecipitation(ChIP)-on-chip (ChIP-chip) or ChIP 
sequencing (ChIP-seq) analysis (49-52). Thus, the study of 
both SVC and preadipocyte lines has made an enormous 
contribution to our current understanding of adipogenesis 
and WAT biology.(23)
 The basic pathways regulating adipogenesis, focusing 
on the limited expandability of SAT and the development of 
hypertrophic obesity with a dysregulated adipose tissue and 
ectopic fat accumulation. Understanding mechanisms that 
limit subcutaneous adipogenesis in humans should provide 
novel targets for the treatment of obesity-related metabolic 
complications. It is well established that subcutaneous 
adipose cell size can differ markedly between individuals 
with the same BMI and amount of body fat,(53) supporting 
the concept that adipogenesis is under differential regulation. 
Interestingly, poor differentiation was seen in individuals 
with large subcutaneous adipose cells (hypertrophic 
obesity), whereas small adipose cells were associated with 
good adipogenesis suggesting a causal relationship. As 
discussed below, this difference was not due to a lack of 
precursor cells in hypertrophic obesity but rather due to 
inappropriate signaling of pathways that promote precursor 
cell differentiation and/or enhanced inhibitory signals 
promoting dedifferentiation, as has been suggested to be the 
case for b-cells in diabetes.(53)
 A key signaling pathway for maintaining precursor 
cells uncommitted and undifferentiated is the wingless  type 
mouse mammary tumor virus integration site family (WNT) 
signaling pathway.(54,55) The transcriptional program 
regulating subsequent differentiation is well characterized, 
peroxisome proliferator-activated receptors (PPAR)-γ and 
CCAAT/enhancer-binding protein-a have been identiied 
as the key regulators of terminal differentiation.(56,57) 
However, there is an array of other regulatory factors of 
importance for this process.
 WNT activation can be terminated by several secreted 
antagonists, including Dickkopf-1 (DKK1), WNT inhibitory 
factor-1, and secreted Frizzled-related proteins (sFRPs), 
although the exact mechanisms for the regulation and 
induction of these molecules are unclear. We have shown 
that PPARγ activation by thiazolidinediones increases 
Figure 2. Relationships between SVCs, ASCs, committed preadipocytes, and mature adipocytes.(23) (Adapted with permission from 
The American Society for Biochemistry and Molecular Biology).
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DKK1 in differentiated 3T3-L1 adipocytes.(58) However, 
this is obviously a late event and cannot account for the 
necessary early termination of WNT signaling needed to 
induce adipogenesis from precursor cells.
 Gustafson et al. recently performed a detailed study 
to characterize WNT activation and its termination during 
adipogenic differentiation of human subcutaneous adipose 
precursor cells from different donors.(59) These indings 
show that a poor ability of adipose precursor cells to 
differentiate is associated with markers of a maintained 
WNT activation and lack of induction of the secreted WNT 
inhibitor DKK1. Furthermore, inhibiting WNT with DKK1 
increases adipogenic differentiation, showing that the low 
ability to differentiate is not due to lack of precursor cells 
but rather to an inability to terminate WNT activation. A low 
degree of differentiation characterizes adipose precursor 
cells from individuals with large adipose cells suggesting 
that hypertrophic obesity is indeed a consequence of the 
impaired ability of precursor cells to differentiate.(5)
 The BMPs have been shown to play an important 
role for the induction of both white adipogenesis (BMP2 
and 4) and brown adipogenesis (BMP7).(59-61) Not only 
is BMP4 able to promote both commitment and subsequent 
differentiation when added to the culture medium but, 
interestingly, BMP4 is also induced in human adipose 
precursor cells during differentiation.(59)
 Taken together, both WNT and BMP4 signaling play 
important roles in adipogenesis by regulating commitment 
as well as subsequent PPARγ activation and differentiation. 
BMP4 promotes commitment and adipogenic differentiation 
of precursor cells, whereas canonical WNT activation is 
inhibitory to both these processes. The WNT1 inducible 
signaling pathway protein-2 (WISP2) plays a key role by 
both preventing the effect of BMP4 to induce precursor cell 
commitment as well as by exerting a direct extracellular 
inhibitory signal on PPARγ activation and adipose cell 
differentiation after its secretion. Thus, WISP2 is situated 
at the crossroad between WNT and BMP4 signaling and 
can play a critical role for the development of hypertrophic 
obesity.
Obesity is characterized by an expansion of WAT 
mass resulting from increased adipocyte number and/
or size.(62) It is a key risk factor leading to T2DM and 
hyperlipidemia, and has become a pan-endemic health 
problem with rapidly growing global incidence.(46,63) 
Obesity is associated with systemic chronic inlammation 
characterized by altered cytokine production and activation 
of inlammatory signaling.(64,65) Abundant studies have 
linked the increased production of inlamatory cytokines, 
such as TNF-α, interleukin (IL)-6, and certain adipokines, 
during the inlammatory process to obesity, as well as to 
the development of insulin resistance.(66-68) Obesity 
characterized by inappropriate expansion of adipose cells 
(hypertrophic obesity) is associated with the metabolic 
syndrome (MetS) and is caused by an inability to recruit 
and differentiate new precursor cells.(59) 
 Interestingly, research has also shown that individuals 
with inappropriately enlarged adipose cells for a given BMI 
(hypertrophic obesity) in the abdominal subcutaneous tissue 
are characterized by a reduced recruitment of new cells, 
suggesting that this is causally related to the development 
of hypertrophic obesity.(53) More important, adipose cell 
size in the abdominal subcutaneous region is, for a given 
BMI, considerably larger in individuals with a genetic 
predisposition for T2DM than in subjects lacking a known 
heredity or in those with a heredity for overweight/obesity.
(69,70) Furthermore, hypertrophic adipocytes, even in 
the absence of obesity per se, are associated with several 
markers of a dysregulated adipose tissue and systemic as 
well as local insulin resistance.(70,71)
 In agreement with these in vivo indings, Isakson 
P, et al. recently showed that the ability of SAT SVC to 
undergo adipogenic differentiation was markedly reduced 
in hypertrophic obesity and that the degree of impairment 
was positively correlated with adipose cell size of the donor.
(55)
 Together, these indings suggest that hypertrophic 
obesity is due to an apparent genetic impairment in the 
ability to recruit and differentiate new subcutaneous 
adipose precursor cells. This, then, promotes inappropriate 
cell enlargement, inlammation, and a dysregulated adipose 
tissue that will favor ectopic lipid accumulation and the 
development of a metabolically obese phenotype.(69,70) 
The concept of lipid storage “overlow” as a consequence 
of the limited expansion of SAT has received much 
experimental support in both human and animal studies. 
The animal model generated by Scherer, et al. (72) with 
overexpression of adiponectin in SAT, induced massively 
obese mice with perfectly normal insulin sensitivity and 
metabolism. Importantly, the adipose tissue in these mice 
was characterized by many small adipose cells-hyperplastic 
obesity. These and many other studies support the concept 
that the ability to recruit new adipose cells in SAT during 
lipid accretion prevents inappropriate adipose cell expansion 
Obesity, Hypertrophic Obesity and 
Metabolically Healthy Obesity
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(hypertrophic obesity) with iniltration of inlammatory 
cells, insulin resistance, and a dysfunctional adipose 
tissue with reduced insulin receptor substrate 1, glucose 
transporter, type 4 (GLUT4), lipoprotein lipase activation, 
adiponectin, and other markers of reduced PPARγ activation.
(73,74) The recruitment and activation of the inlammatory 
cells in the adipose tissue may be a consequence of both 
necrotic enlarged adipose cells and tissue factors promoting 
a proinlammatory phenotype.(75,76)
 Hypertrophic obesity is associated with inlammation 
and increased cytokine production and release, which can 
inhibit PPARγ activation, the key mediator of the fully 
differentiated and insulin-sensitive adipose cell phenotype.
(55) Overall, the adipose tissue becomes dysfunctional 
both in terms of taking up lipids from the bloodstream via 
lipoprotein lipase activation, secreting adiponectin and other 
apparently protective adipokines and, instead, increasing 
the secretion of insulin-antagonistic and proinlammatory 
molecules also associated with increased lipolysis and FFA 
release.(5)
 Promoting adipose cell recruitment in SAT rather 
than merely inlating the cells would be protective of 
the obesity-associated metabolic complications. In 
fact, this is a fundamental mechanism of action of the 
thiazolidinediones,(77) also leading to reduced ectopic fat 
while the subcutaneous depot becomes expanded and less 
insulin resistant,(77,78) but their unwanted side effects have 
abnormalities are not found in all obese people (85,86), 
as evidenced by the occurrence of a subset of apparently 
healthy obese subjects referred to as metabolically healthy 
obese (MHO).(87,88) Several studies have conirmed the 
existence of MHO individuals (89-95), accounting for as 
much as 40% of the obese population. MHO individuals 
display a favorable metabolic proile, characterized by 
high levels of insulin sensitivity, a low prevalence of 
hypertension, and a favorable lipid and inlammation proile. 
The MHO phenotype is strongly associated with a smaller 
visceral depot, although not necessarily with expanded 
subcutaneous; the clamped glucose infusion rate strongly 
correlates with visceral WAT area.(96)
 In humans, WAT ibrosis as measured by collagen VI 
expression is positively correlated with insulin resistance 
and inlammatory markers, such as the number of adipose 
tissue macrophages (ATMs).(97) The relationship between 
stress/ibrosis and unhealthy WAT (98) supports a hypothesis 
that alleles of genes that encode different forms of collagen 
or enzymes that modify collagen, such as lysyl oxidase,(99) 
correlate with the ability of WAT to expand and remodel in 
obesity while avoiding stress and remaining metabolically 
healthy. 
 A hypothesis follows that some MHO humans will 
show increased adipogenesis, based on functional allelic 
variants of PPARγ, peroxisome proliferator-activated 
receptor gamma coactivator 1 - alpha (PGC-1α), PR domain 
containing (PRDM)16 or other components of the adipogenic 
transcriptional program that expand subcutaneous WAT.
(79)
Visceral storage capacity is relatively low compared 
to subcutaneous. Without available storage, lipid is 
distributed to hepatic, cardiac, skeletal muscle and other 
highly undesirable locations, called ectopic fat deposition 
(100), contributing to metabolic damage. Ectopic fat arises 
upon insuficient adipogenesis in the obese, prediabetic 
individual.(101)
 Adipocytes are individually ‘wrapped’ in a supporting 
sheath of extracellular matrix (ECM), in particular collagens. 
Remodeling of the ECM, and cycles of collagen breakdown/ 
re-deposition in particular, are essential for adipocyte and 
adipose tissue expansion.(102) However, in the obese state, 
excessive, dysregulated deposition of collagens and other 
ECM components (i.e., ibrosis) eventually constrains 
adipocyte expansion, thereby promoting adipocyte stress, 
Figure 3. A classiication model for obese and metabolic 
phenotypes. A ‘two-by-two’ map of the effects of obesity on health, 
with two off-diagonal entries.(79) MONW: metabolically obese 
normal weight; MHO: metabolically healthy obese. (Adapted with 
permission from Elsevier). 
limited the usefulness of this class of drugs.
 Obesity is a major public health problem that has 
reached epidemic proportions worldwide.(80) It is associated 
with numerous metabolic and cardiovascular disturbances 
such as insulin resistance, T2DM, hypertension, and 
dyslipidemia.(81-84) However, these cardiometabolic 
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inlammatory/stress kinase activation, and resulting 
systemic metabolic dysfunction.(103-106)
 Collagen VI is speciically implicated in the 
pathogenesis of obesity-associated adipose tissue ibrosis 
and metabolic dysfunction, as collagen VI deposition is 
increased in WAT of obese, insulin resistant humans,(97) and 
the absence of this ECM component in obese (knockout) mice 
permits greater adipocyte hypertrophy while normalizing 
key metabolic parameters.(105) Collagen VI deposition and 
adipose tissue ibrosis in human WAT is coincident with the 
presence of ‘alternatively activated’ (CD150+) ATMs that 
are known to promote ECM remodeling and wound healing.
(107)
 One potential emerging mechanism involves the 
endoplasmic reticulum (ER), the organelle responsible for 
protein folding, maturation, quality control, and traficking. 
When the ER becomes stressed due to the accumulation of 
newly synthesized unfolded proteins, the unfolded protein 
response (UPR) is activated. The three branches of the 
canonical UPR intersect with a variety of inlammatory 
and stress signaling systems including the NFkB-IkB 
kinase (IKK) and JNK-AP1 pathways, as well as networks 
activated by oxidative stress, all of which can inluence 
metabolism.(108)
 A close examination of ER stress and UPR pathways 
has demonstrated many links to major inlammatory and 
stress signaling networks, including the activation of the 
JNK-AP1 and NFkB-IKK pathways (109,110), as well as 
production of reactive oxygen species (ROS) and nitric 
oxide.(111,112) Notably, these are also the pathways and 
mechanisms that play a central role in obesity-induced 
inlammation and metabolic abnormalities, particularly 
abnormal insulin action.(65) Given that the UPR is closely 
integrated with stress signaling, inlammation, and JNK 
activation and the fact that obesity stresses the ER (due 
to an increase in synthetic demand, alterations in energy 
availability, and activation of inlammatory pathways), 
Hotamisligil have postulated that obesity may lead to ER 
stress in metabolically active tissues.(108)
 Obesity is a condition where the organism needs 
to adapt to and function under chronic exposure to high 
energy and nutrient intake. This adaptation alone increases 
the demand on the synthetic and storage machinery at 
several sites, including liver, adipose tissue, and pancreas, 
all of which are central players in metabolic homeostasis. 
Hence, the major cell types controlling systemic metabolic 
homeostasis may become highly sensitive to ER stress under 
conditions of obesity. This is due to increased demands 
on the synthetic machinery as a result of nutrient excess, 
saturation of storage capacity, and many other factors, 
which together create a challenging milieu in which the ER 
must carry out its regular functions and sustain its protein-
folding capacity.
 ER stress and the UPR are connected to inlammatory 
pathways and may contribute to the production of 
inlammatory mediators. Conversely, inlammation can 
also induce or propagate the UPR.(108) Obesity is a state 
of chronic low-grade systemic inlammation. This chronic 
inlammation is deeply involved in insulin resistance, 
which is the underlying condition of T2DM and MetS. 
A signiicant advance in our understanding of obesity-
associated inlammation and insulin resistance has been 
recognition of the critical role of ATMs.
 Importantly, tissue macrophages are phenotypically 
heterogeneous and have been characterized according to 
their activation/polarization state as M1 (or “classically 
activated” proinlammatory macrophages) or M2 (or 
“alternatively activated” noninlammatory macrophages.
(113-116) In addition to the absolute number of macrophages 
recruited to adipose tissue, the polarization status of 
macrophages also inluences obesity pathogenesis. 
 M2 ATMs predominate in lean mice, whereas obesity 
induces the accumulation of M1 ATMs with high expression 
of TNF-α, IL-6 and inducible nitric oxide synthase,(115) 
leading to a proinlammatory environment in WAT. M2 
macrophages produce anti-inlammatory molecules, 
including IL-10 and the IL-1 receptor antagonist IL-1RA, 
and are induced in response to the T helper type 2–associated 
cytokines IL-4 and IL-13.(115)
 Obesity-related events promote the recruitment of 
M1 macrophages into adipose tissue, and during obesity, 
M1 macrophages are by far the dominant macrophage 
population present in fat. Notably, many studies have 
demonstrated that tipping the balance back in favor of M2 
macrophages during obesity promotes improved metabolic 
function and less adipose inlammation.(117) Consistent 
with that, the treatment of obese mice with omega-3 fatty 
acids or thiazolidinediones has been shown to ameliorate 
metabolic disease through the induction of M2 macrophages.
(118,119) It has been discovered that the transcription factor 
PPAR-g directs the transcriptional programming of M2 
macrophages.(120)
Fat is not homogeneous. Depot-dependent differences 
among preadipocytes, from which new fat cells arise, appear 
to be inherent. These inherent mechanisms, combined with 
local variation in fat-depot cellular composition, circulation, 
Adipose Tissue Dysfunction
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and neurological and other factors, probably account for 
regional differences in fat-tissue size and function. Sex, 
obesity, or other factors also have fat-depot dependent effects 
on cellular composition, the paracrine microenvironment, 
and adipose function. Thus, different fat depots are separate 
miniorgans.(10)
 Immediate questions include whether visceral 
obesity is a manifestation of a general process that leads 
to systemic metabolic dysfunction, whether it is causal, or 
whether subcutaneous fat dysfunction initiates both visceral 
obesity and metabolic disease. Evidence is mounting in 
favor of the latter. The relationship between inlammation 
and MetS is supported by several studies (65,121-123), as 
is the relationship between increased visceral fat mass and 
MetS.(124-126) However, there is a paucity of data on SAT 
biology in the pathogenesis of MetS.(127)
 SAT which comprises ∼80% of adipose tissue and 
is the major source of fatty acids for the liver is readily 
accessible to study and has been shown to be metabolically 
correlated to indices of insulin resistance as well as to VAT.
(128-131) In addition to intraabdominal fat, investigators 
have shown that the amount of SAT in subjects with MetS 
positively correlates with increasing MetS factor scores and 
negatively correlates with circulating adiponectin levels.
(132) Other investigators have also reported that SAT is 
signiicantly associated with MetS and increases with the 
increasing number of MetS features, independent of age and 
sex.(133) Furthermore, inlammatory cells and processes, 
such as macrophage iniltration, appear to be important 
in adipose tissue inlammation. Speciically, investigators 
have examined abdominal SAT from obese subjects and 
reported that an inlamed adipose phenotype characterized 
by tissue macrophage accumulation in crownlike structures 
(CLSs) is associated with systemic hyperinsulinemia and 
insulin resistance and impaired endotheliumdependent 
low-mediated vasodilation.(134) Macrophage retention in 
fat was also linked to upregulated tissue CD68 and TNF-a 
mRNA expressions in addition to increased plasma high-
sensitivity C-reactive protein (hsCRP) concentrations. As 
such, Bremer study has focused on the potential role of SAT 
dysregulation in the syndrome’s pathogenesis.(135)
 Importantly, there was also a signiicantly higher 
release of chemerin from SAT in subjects with MetS 
which persisted following adjustment for BMI or waist 
circumference (WC) and age. In addition, there was a 
signiicantly lower secretion of omentin from SAT in 
subjects with MetS which persisted following adjustment 
for both age and BMI or WC. However, the secretion of 
both resistin and visfatin from SAT was not signiicantly 
different between the MetS and control groups.(135) 
 In addition, Bremer, et al. have recently demonstrated 
abnormal circulating and SAT-secreted chemerin and 
omentin-1 levels in subjects with nascent MetS.(136) 
Chemerin is a novel adipokine that is produced by both 
adipose tissue and liver; moreover, it is a chemoattractant for 
immune cells such as macrophages and promotes adipocyte 
differentiation.(137) Chemerin levels have also been shown 
to be higher in obesity, some features of MetS, diabetes, and 
nonalcoholic fatty liver disease,(138-139) and it appears to 
induce insulin resistance in skeletalmuscle, the major site of 
peripheral insulin resistance.(140)
 As opposed to chemerin, omentin is predominantly 
expressed and secreted by VAT (141,142) and appears to 
have insulin-sensitizing actions.(142) Furthermore, its 
levels are lower with both obesity and diabetes.(143) This 
data, as well as data fromother investigators, thus, highlight 
the importance of SAT dysfunction in subjects with MetS 
and its contribution to the proinlammatory state and insulin 
resistance.
Conclusion
Subcutaneous fat tissue dysfunction, with failed 
adipogenesis, decreased lipid-storage capacity, and 
inlammation, could lead to ectopic fat deposition, with 
expansion of visceral fat as an indicator rather than the 
cause of lipotoxicity. Therefore, enhancing subcutaneous 
fat tissue function is potentially a better approach for 
treating metabolic syndrome than eliminating visceral fat. 
Indeed, TZDs may work this way. If further experimental 
results indicate that this speculation has merit, screening 
for compounds that enhance subcutaneous preadipocyte 
replication and adipogenesis might lead to effective 
treatments for preventing complications of metabolic 
syndrome.
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